To analyze the safety risks of blood products during the COVID-19 pandemic, and to study the emergency countermeasures of the World Health Organization (WHO), the US FDA (FDA) and the Plasma Protein Therapeutics Association (PPTA) to ensure the safety of blood products during the COVID-19 pandemic, in order to suggest improvements for blood product regulation in China in response to public health emergencies. This article uses literature review, comparative research and descriptive research methods to analyze the existing problems of blood product regulation in response to public health emergencies during the COVID-19 pandemic. When responding to sudden epidemic situations or infectious public health emergencies, Chinese government regulatory agencies should strengthen communication and cooperation with blood product manufacturers, industry associations, and professional consulting teams, providing timely scientific industry guidelines to give a full play as the role of industry associations so as to ensure the safety of blood products on the market.